Ocuphire Pharma, Inc. logo

Ocuphire Pharma, Inc.


Overview | Financials
Company Name Ocuphire Pharma, Inc.
Symbol OCUP
Currency USD
Price 1.79
Market Cap 46,404,318
Dividend Yield 0%
52-week-range 1.5 - 4.58
Industry Biotechnology
Sector Healthcare
CEO Mr. Richard J. Rodgers M.B.A.
Website https://www.ocuphire.com

An error occurred while fetching data.

About Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light

Related Stocks

Neoleukin Therapeutics, Inc. logo

Neoleukin Therapeutics, Inc.


3.49 USD

Zynerba Pharmaceuticals, Inc. logo

Zynerba Pharmaceuticals, Inc.


1.3 USD

Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc.


9.59 USD

IN8bio, Inc. logo

IN8bio, Inc.


1.02 USD

Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc.


1.56 USD

Acasti Pharma Inc. logo

Acasti Pharma Inc.


2.705 USD


Numbers are in millions USD

Numbers are in millions USD